Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Alvotech - Ordinary Shares
(NQ:
ALVO
)
14.39
-0.07 (-0.48%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Alvotech - Ordinary Shares
< Previous
1
2
3
4
Next >
Alvotech Completes $137 Million Private Share Placement
January 23, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate
January 13, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
January 11, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
January 06, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
January 06, 2023
From
Alvotech
Via
GlobeNewswire
Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira®
December 22, 2022
From
Alvotech
Via
GlobeNewswire
Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT to headline field
December 16, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech Completes $59.7 Million Private Placement
December 16, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech Shares Start Trading on Nasdaq Iceland Main Market
December 08, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech and STADA Broaden Access to Hukyndra® adalimumab biosimilar in Europe
December 07, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech Announces Changes to its Leadership Team
December 01, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech Secures Financing Facilities of Approximately $136 Million
November 16, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech Reports Financial Results for First Nine Months of 2022 And Provides Business Update
November 16, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech Announces Australian Marketing Authorization for AVT02, a Biosimilar to Humira®
November 14, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech to Present Switching Study Data for AVT02, a Proposed Biosimilar to Humira®, at 2022 American College of Rheumatology Conference
November 10, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech to Report First Nine Months Financial Results on November 15, 2022 and Host Business Update Conference Call at 8:00 am ET on November 16, 2022
October 27, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech to Participate in Upcoming Jefferies London Healthcare Conference in November
October 26, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech and JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates for Canadian Market, Bringing New Options for Patients in Specialty Care
October 19, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech’s Partner Submits Application for Marketing Approval of First Biosimilar Candidate in Japan
October 17, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech Appoints Sarah Tanksley as Chief Quality Officer
October 11, 2022
From
Alvotech
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.